A change in a transcript identifies an observation in the sampled system at a particular time. It doesn't establish direct binding to the corresponding receptor or a behavioral benefit. Appropriate controls help distinguish a compound associated response from handling or background effects. The interpretation should preserve both the model and the measurement level.
Representative product imagery. Verify the physical label and lot documentation on receipt.
Neuro Research
Selank
In stock·Ships in 1–2 business days
Selank peptide supplied in a 10 mg research vial. Each unit is labeled with a traceable lot code and links to its corresponding analytical report.
Select size2 options
Select pack sizeSave 18% on kits
1 × 10 mg$41.99
In stockSelected size 10 mgSC-SEL-010
Transparent volume pricing10-vial peptide kits save 18%.
Secure checkout US & EU dispatch
Research use only acknowledgment required at checkout
Published report · Lot 2025283
Reports describe the tested lot. Match the lot on your label before interpreting results.
Compound context
What researchers study
Selank peptide is a synthetic sequence associated with tuftsin derived research. Laboratories investigate its identity and responses in defined neurobiological systems. The available quantities on this page describe reference material for research. They do not provide an anxiety treatment, a nasal formulation or a personal administration schedule.
Published experiments have examined expression of genes associated with GABAergic neurotransmission in animal tissue and cell models. A gene expression change is not the same as direct receptor binding or an established clinical effect. Selank benefits claims should retain that distinction. Similarity between expression patterns can suggest further experiments without identifying a complete mechanism.
Sampling time can change which genes appear to respond. The biological model and normalization method also affect interpretation. An experiment needs to define whether the question concerns transcription, protein abundance or a functional outcome. Those measurements can inform one another, but none should silently be substituted for another in a conclusion.
Scope limitMatch the sequence and supplied form to the current lot report. Research use excludes personal dosing or treatment claims. Modified variants require their own identity assessment and should not be assumed equivalent to the base sequence.
Serenity Compounds is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Common laboratory focus
The two names refer to different sequences with different research histories. A shared catalog area does not make them substitutes in a method. Semax and selank comparisons should state the endpoint and use documented materials. An absence of a suitable direct comparison cannot be filled by ranking unrelated studies.
Terminal modifications or other sequence changes can affect analytical identity and experimental behavior. A report for one variant doesn't certify another. Retain the full material designation and expected molecular weight in the calculation record. A similar product nickname isn't enough to justify using a modified peptide in place of the required reference.
Quality documentation
Know what your laboratory receives.
Batch records are published for transparency and should be independently reviewed by qualified research personnel.
Current certificateSelank · Lot 2025283Liquilabs s.r.o.View report
- Tamper-evident packaging
- Lot and SKU traceability
- Independent analytical review
Continue exploring
